Concourse Financial Group Securities, Inc. Tyme Technologies, Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $1.64 Billion
  • Q3 2024

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 09, 2022
BUY
$0.23 - $0.35 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$0.28 - $0.68 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$0.6 - $1.04 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$0.99 - $1.38 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$1.14 - $1.87 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021
BUY
$1.34 - $3.53 $0 - $0
0 New
0 $0
Q4 2020

Feb 02, 2021
BUY
$0.87 - $1.26 $0 - $0
0 New
0 $0
Q3 2020

Nov 13, 2020
BUY
$0.93 - $1.35 $0 - $0
0 New
0 $0
Q2 2020

Aug 13, 2020
BUY
$0.97 - $1.7 $0 - $0
0 New
0 $0
Q1 2020

May 13, 2020
BUY
$0.9 - $1.95 $0 - $0
0 New
0 $0
Q4 2019

Feb 14, 2020
BUY
$1.0 - $1.49 $0 - $0
0 New
0 $0
Q3 2019

Nov 13, 2019
BUY
$0.97 - $1.77 $0 - $0
0 New
0 $0
Q2 2019

Aug 13, 2019
BUY
$0.96 - $1.89 $0 - $0
0 New
0 $0
Q1 2019

May 15, 2019
BUY
$1.76 - $3.73 $0 - $0
0 New
0 $0
Q4 2018

Feb 14, 2019
BUY
$2.01 - $4.21 $0 - $0
0 New
0 $0
Q3 2018

Nov 13, 2018
BUY
$2.18 - $3.44 $0 - $0
0 New
0 $0

About TYME TECHNOLOGIES, INC.

TYME Quotes by TradingView
  • Ticker TYME
  • Exchange NASDAQ
  • Shares Outstandng 172,207,008
  • Description
  • Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...
More about TYME
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email